Innate Pharma (IPHYF) 15.8300 $IPHYF
Clearance of global agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
GlobeNewswire - Tue Jul 07, 12:36AM CDT
CLEARANCE OF CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA AND RECEIPT BY INNATE PHARMA OF $250M INITIAL PAYMENT
ArGEN-X: Forging The Future Of Antibodies
Logribel Biostocks - at Seeking Alpha - Tue Jun 09, 1:14PM CDT
SHPG: 250.34 (+7.35), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), GLPG: 53.06 (+0.56)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Selling Innate Short
EP Vantage - at Seeking Alpha - Sat Apr 25, 7:40AM CDT
Ordinarily a $250m up-front payment for a phase I/II asset would seem generous, but when it comes in a bull market and concerns a red-hot immuno-oncology project - Innate Pharma's ( OTCPK:IPHYF ) IPH2201 - some investors might wonder whether the...
AZN: 66.45 (+1.90)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 66.45 (+1.90), JUNO: 52.05 (+1.72), CELG: 118.84 (+1.97)
AstraZeneca and Innate Pharma team up cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:51AM CDT
AZN: 66.45 (+1.90)
Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate's site-specific conjugation technology
GlobeNewswire - Thu Apr 16, 12:38AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases, today announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates ("ADC"
.
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
INNATE PHARMA : DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
GlobeNewswire - Thu Mar 26, 1:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB" completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol.
Innate Pharma (IPHYF) CEO Herve Brailly on Full Year 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 20, 6:50PM CST
INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
ARIA: 7.92 (+0.13)
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
BMY: 69.27 (+1.38)
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
BMY: 69.27 (+1.38)
Clearance of global agreement with AstraZeneca and receipt by Innate Pharma of $250m initial payment
GlobeNewswire - Tue Jul 07, 12:36AM CDT
CLEARANCE OF CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA AND RECEIPT BY INNATE PHARMA OF $250M INITIAL PAYMENT
ArGEN-X: Forging The Future Of Antibodies
Logribel Biostocks - at Seeking Alpha - Tue Jun 09, 1:14PM CDT
SHPG: 250.34 (+7.35), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), GLPG: 53.06 (+0.56)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H1 2015
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hl8ss/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Soligenix, Inc. - Taiwan Liposome Company, Ltd. For more information visit http://www.researchandmarkets.com/research/4h...eous_tcell
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
Selling Innate Short
EP Vantage - at Seeking Alpha - Sat Apr 25, 7:40AM CDT
Ordinarily a $250m up-front payment for a phase I/II asset would seem generous, but when it comes in a bull market and concerns a red-hot immuno-oncology project - Innate Pharma's ( OTCPK:IPHYF ) IPH2201 - some investors might wonder whether the...
AZN: 66.45 (+1.90)
AstraZeneca Inks Multiple Deals, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:43PM CDT
AstraZeneca's (AZN) global biologics research and development arm, MedImmune, inked deals with Innate Pharma, Celgene and Juno related to its anti-PD-L1 immune checkpoint inhibitor, MEDI4736.
AZN: 66.45 (+1.90), JUNO: 52.05 (+1.72), CELG: 118.84 (+1.97)
AstraZeneca and Innate Pharma team up cancer
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 9:51AM CDT
AZN: 66.45 (+1.90)
Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate's site-specific conjugation technology
GlobeNewswire - Thu Apr 16, 12:38AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases, today announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates ("ADC"
. Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 99.53 (+1.13), CYCC: 0.72 (-0.01), ONCS: 5.75 (-0.06), NVS: 103.22 (+3.20), KPTI: 25.57 (+0.24)
INNATE PHARMA : DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
GlobeNewswire - Thu Mar 26, 1:36AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB"
completed its fourth assessment of the EffiKIR study and recommended to stop treatment in one arm and continue the trial with the remaining two arms as per protocol. Innate Pharma (IPHYF) CEO Herve Brailly on Full Year 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 20, 6:50PM CST
INNATE PHARMA: First Phase II trial with IPH2201 open in head and neck cancer
GlobeNewswire - Fri Dec 19, 12:41AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charite Comprehensive Cancer Center (CCCC), Berlin, Germany.
INNATE PHARMA announces its 2015 FINANCIAL CALENDAR as well as its participation in upcoming investor conferences
GlobeNewswire - Tue Dec 02, 12:34AM CST
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces today its tentative financial calendar for 2015, which is set as follows:
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US
ARIA: 7.92 (+0.13)
Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.
BMY: 69.27 (+1.38)
INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015
BMY: 69.27 (+1.38)
